Scott Middleton, MD
Family Medicine · la Habra, CANPI 1497742621
Payments from drug & device makers
Across 683 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- AstraZeneca$1K
- Johnson & Johnson$1K
- plus $7K from 29 others
What the payments were for
- Consulting fees$1,2208%
- Speaking & faculty fees$1,2258%
- Travel & lodging$560%
- Food & beverage$11,94682%
- Education$1941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 79 | $1,579 |
| Novo Nordisk | 106 | $1,480 |
| Biohaven Pharmaceuticals, Inc. | 10 | $1,411 |
| AbbVie(2 entities) | 68 | $1,236 |
| AstraZeneca | 37 | $1,030 |
| Johnson & Johnson | 73 | $1,005 |
| GSK | 50 | $942 |
| Amgen(2 entities) | 48 | $863 |
| Astellas Pharma US Inc | 37 | $810 |
| BD | 1 | $700 |
| Sanofi-aventis U.S. LLC | 8 | $626 |
| Boehringer Ingelheim | 29 | $571 |
| Pfizer | 33 | $467 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $360 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $331 |
| Merck | 12 | $202 |
| Bayer | 8 | $142 |
| Novartis | 7 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $134 |
| Radius Health, Inc. | 3 | $127 |
| Antares Pharma, Inc. | 4 | $91 |
| Therapeuticsmd, Inc. | 4 | $70 |
| Promius Pharma LLC | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Boston Scientific | 1 | $39 |
| Optos, Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Shire North American Group Inc | 1 | $22 |
| Sobi, Inc | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- SOLIQUA 100/33$275
- Ozempic$258
- TOUJEO$250
- Tresiba$142
- XARELTO$125
- FARXIGA$121
- Tymlos$114
- EVENITY$112
- MOUNJARO$104
How this compares
$14,640 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 173 | $176,650 |
| JardianceEmpagliflozin | 132 | $155,276 |
| OzempicSemaglutide | 127 | $150,758 |
| FarxigaDapagliflozin Propanediol | 150 | $135,571 |
| TrulicityDulaglutide | 117 | $133,315 |
| MounjaroTirzepatide | 75 | $98,309 |
| MyrbetriqMirabegron | 76 | $83,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $78,901 |
| XareltoRivaroxaban | 43 | $51,610 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $36,551 |
| JanuviaSitagliptin Phosphate | 20 | $32,191 |
| ProliaDenosumab | 13 | $21,822 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $19,548 |
| Methyltestosterone | 11 | $18,461 |
| LinzessLinaclotide | 18 | $18,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,579 | $231,624192 claims |
| PfizerEliquis | $467 | $176,650173 claims |
| Novo NordiskOzempic, Rybelsus | $1,480 | $167,762143 claims |
| Boehringer IngelheimJardiance | $571 | $155,276132 claims |
| AstraZenecaFarxiga | $1,030 | $135,571150 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $942 | $108,838126 claims |
| Astellas Pharma US IncMyrbetriq | $810 | $83,80276 claims |
| MerckJanumet, Januvia | $202 | $68,74245 claims |
| Johnson & JohnsonXarelto | $1,005 | $51,61043 claims |
| AbbVieLinzess, Synthroid | $1,236 | $23,32998 claims |
| AmgenProlia | $863 | $21,82213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in la Habra
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.